BridgeBio Oncology Therapeutics, Inc. Logo

BridgeBio Oncology Therapeutics, Inc.

Clinical-stage biopharma developing inhibitors for genetically driven cancers.

BBOT | US

Overview

Corporate Details

ISIN(s):
KYG4444H1011
LEI:
Country:
United States of America
Address:
256 E. GRAND AVENUE, SUITE 104, 94080 SOUTH SAN FRANCISCO

Description

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops a pipeline of novel, bioavailable small molecule inhibitors designed to treat patients with RAS-dependent cancers and other malignancies with clear genetic drivers. Its core strategy centers on inhibiting active RAS, aiming to create transformative medicines that advance beyond current therapeutic approaches. BBOT was launched to accelerate the development of its parent company's precision oncology portfolio.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all BridgeBio Oncology Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BridgeBio Oncology Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BridgeBio Oncology Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celltrion Pharm Inc. Logo
Manufactures and supplies chemical pharmaceuticals and biosimilar products.
South Korea
068760
Develops and manufactures medical devices, tissue grafts, and advanced biologics.
South Korea
049180
Celon Pharma S.A. Logo
An integrated pharmaceutical company researching and manufacturing modern drugs.
Poland
CLN
Celularity Inc Logo
Develops allogeneic cell therapies and biomaterials from the human placenta.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Clinical-stage pharmaceutical company developing medicines for unmet medical needs.
United States of America
CNTA
Century Therapeutics, Inc. Logo
Develops iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases.
United States of America
IPSC
Cereno Scientific AB Logo
Clinical-stage biotech developing drugs for rare cardiovascular & pulmonary diseases.
Sweden
CRNO
CERO THERAPEUTICS HOLDINGS, INC. Logo
Immunotherapy company developing engineered T cell therapeutics for cancer treatment.
United States of America
CERO
CERUS CORP Logo
Develops pathogen inactivation technology to reduce transfusion-transmitted infections.
United States of America
CERS
Cessatech A/S Logo
A biotech company developing medicines for children's acute pain management.
Denmark
CESSA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.